Stocks Comparison
COSCIENS Biopharma vs Karbon-X: revenue, profit, margins and growth compared
COSCIENS Biopharma brought in $7.5M of revenue in fiscal 2025, Karbon-X $55.9M in fiscal 2026. Revenue changed by -21.8% at COSCIENS Biopharma and +1,665.6% at Karbon-X on the year before, so Karbon-X grew faster. COSCIENS Biopharma kept -138.1% of its revenue as net profit, Karbon-X -24.3%. Free cash flow was -$9.2M at COSCIENS Biopharma and -$7.9M at Karbon-X.
Side by side, latest fiscal year
| CSCID | KARX | |
|---|---|---|
| Fiscal year ended | FY2025 (December 31, 2025) | FY2026 (May 31, 2026) |
| Revenue | $7.5M | $55.9M |
| Revenue growth | -21.8% | +1,665.6% |
| Net income | -$10.4M | -$13.6M |
| Net margin | -138.1% | -24.3% |
| Free cash flow | -$9.2M | -$7.9M |
| Free cash flow margin | -122.4% | -14.1% |
| Earnings per share (diluted) | -$3.27 | -$0.16 |
| Cash | $7.3M | $1.2M |
| Debt | n/a | $4.9M |
| Price to earnings | n/a | n/a |
| Market value | n/a | $14.8M |
| Dividend yield | n/a | n/a |
| Rank by revenue in sector | #131 of 154 · Consumer staples | #101 of 154 · Consumer staples |
Over the years
Questions about COSCIENS Biopharma and Karbon-X
Which is bigger by revenue, COSCIENS Biopharma or Karbon-X?
Karbon-X is bigger by revenue: $55.9M in fiscal 2026, against $7.5M for COSCIENS Biopharma in fiscal 2025.
Which keeps more of its revenue as profit, COSCIENS Biopharma or Karbon-X?
COSCIENS Biopharma had a net margin of -138.1% in fiscal 2025; Karbon-X had -24.3% in fiscal 2026.
Which grew revenue faster, COSCIENS Biopharma or Karbon-X?
In their latest fiscal years revenue changed by -21.8% at COSCIENS Biopharma and +1,665.6% at Karbon-X.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.